February 16, 2015
FOR IMMEDIATE RELEASE
DENVER DOCTOR LEADS STUDY OF PROMISING TREATMENT FOR
JAMA Neurology publishes study by Dr. Richard Nash of Presbyterian/St. Luke’s Medical Center on High-dose Immunosuppressive Therapy followed by hematopoietic cell transplantation in Multiple Sclerosis patients
DENVER, Colo. — [Dec. 29, 2014] — Today, Presbyterian/St. Luke’s Medical Center (P/SL) announced a study published by the Journal of the American Medical Association Neurology authored by Dr. Richard Nash of The Colorado Blood Cancer Institute at P/SL showing promising treatment for Multiple Sclerosis (MS). The study found the new treatment is proving to suppress symptoms of the most common type of MS for up to three years.
The article, which is written after a phase 2 clinical trial, indicates that high-dose immunosuppressive therapy and hematopoietic cell transplantation treatments effectively help patients with Relapsing-Remitting Multiple Sclerosis (RRMS). RRMS is the most common form of MS, an autoimmune disease that causes inflammation of the insulating membranes that surround nerves within the central nervous system.
"We are seeing that, after this treatment, patients have long periods of remission from the disease. During this time of remission, the patients are not required to take any additional MS medications,” said Dr. Nash. "After three years, this treatment was associated with improved overall function in the study group and about 80% of patients had no evidence of MS disease activity. High-dose immunosuppressive therapy and hematopoietic cell transplantation for MS still need to go through randomized phase 3 clinical trials but these results are promising and show that long-term control of disease activity in MS may be possible."
Twenty-five patients underwent high-dose immunosuppressive therapy and hematopoietic cell transplantation treatments and then were followed for a three year period. The majority saw remission of MS symptoms and no further evidence of disease activity. To date, the patients have not reported any significant neurological adverse events as a results of the treatments.
The full report was published in the Dec. 29 issue of the Journal of the American Medical Association Neurology. Read the full article online>>
Media Coverage of the Study:
For more than 130 years, P/SL has been meeting the healthcare needs of patients and their families from across the Rocky Mountain and Great Plains regions, and from around the world. With over 80 specialties, 1,000 specialists and primary care physicians, and 1,600 employees, P/SL is the only tertiary/quaternary care hospital in a seven state region that offers one campus with leading comprehensive care, featuring Advanced Centers for Minimally Invasive Surgery, Cardiovascular Services, Cancer/BMT, Pediatrics, Maternal-Fetal Care, Orthopedics, Kidney Transplant, HBO, Wound Healing, Infectious Diseases and more. P/SL provides compassionate and innovative care. Licensed for 680 beds, P/SL is the largest hospital in Colorado.
# # #